Hongjun Li

Dr. Hongjun Li


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
NHNanjun Hu
Nanjun Hu
LBLulu Bai
Lulu Bai
EDEnyong Dai
Enyong Dai
LHLeng Han
Leng Han
RKRui Kang
Rui Kang
DTDaolin Tang
Daolin Tang

1 January 2021 in Journal of Cancer
Verified
Journal Article
Open access
YJYuan-Yuan Jia
Yuan-Yuan Jia
YYYue Yu
Yue Yu
HLHongjun Li
Hongjun Li
Periostin (POSTN) is an extracellular matrix (ECM) protein, involved in various diseases. This research focused on the detailed mechanisms study of periostin (POSTN) overexpression in renal cell carcinoma (RCC) invasion and migration. Western blot and RT-PCR were performed to explore POSTN expression in various RCC cells. Cells were transfected with siRNAs or lentivirus to regulate the expression of POSTN. The effects of POSTN on cell viability, apoptosis, migration, invasion and epithelial-to-mesenchymal transition (EMT) of RCC cells were determined by CCK-8, flow cytometry, migration and invasion assay and Western blot analysis. POSTN expression was significantly enhanced in RCC cells compared with renal tubular epithelial cells. In vitro experiments showed that POSTN knockdown could dramatically inhibit RCC cell proliferation, migration and invasion, while overexpression of POSTN could promote these biological behaviors. We further demonstrated that POSTN knockdown suppressed epithelial-mesenchymal transition (EMT), which was mediated via upregulation of E-cadherin and downregulation of N-cadherin and vimentin, through IKL/AKT/mTOR pathway. In contrast, overexpression of POSTN could promote EMT in RCC cells via the activation of IKL /AKT/mTOR pathway. Next, we demonstrated that higher POSTN expression promoted angiogenesis in vivo in an RCC xenograft tumor via activating IKL /AKT/mTOR pathway. Our study showed that POSTN could promote EMT through ILK/AKT/mTOR pathway and might be an alternative therapeutic strategy for RCC treatment.

10 December 2023 in Renal Failure
Verified
Journal Article
Open access
YYYue Yu
Yue Yu
YJYuan-Yuan Jia
Yuan-Yuan Jia
HLHongjun Li
Hongjun Li
Diabetes mellitus (DM) is a metabolic disease and one of the three major noncommunicable chronic diseases in the world. Research data shows that DM is the leading cause of end-stage dialysis treatm...

12 January 2021 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
YYYue Yu
Yue Yu
YJYuan-Yuan Jia
Yuan-Yuan Jia
MWMeng Wang
Meng Wang
LMLin Mu
Lin Mu
HLHongjun Li
Hongjun Li
Background: Diabetic nephropathy (DN) is a primary complication of diabetes mellitus (DM). The pathology of DN is still vague, and diagnostic accuracy is not enough. This study was performed to identify miRNAs and genes that have possibilities of being used as therapeutic targets for DN in type 2 DM. Methods: Human miRNA data GSE51674 and gene data GSE111154 were downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) and miRNAs (DEmiRNAs) in the kidney between control and DN patients were screened out. The competing endogenous RNA (ceRNA) network was constructed, and key lncRNA-miRNA-mRNA pairs were selected accordingly. Potential drugs targeting DEGs were screened out and validated using PCR analysis. Results: Totally, 83 DEmiRNAs and 293 DEGs were identified in GSE51674 and GSE111154, respectively. Thirteen of the top 20 DEmiRNAs (10 up and 10 down) targeted to 47 DEGs. In the ceRNA network, RP11-363E7.4/TTN-AS1/HOTAIRM1-hsa-miR-106b-5p-PTGER3 and LINC00960-hsa-miR-1237-3p-MMP-2 interaction pairs were identified as the key ceRNA network. Interestingly, PTGER3 and hsa-miR-1237-3p were downregulated, and MMP-2 and hsa-miR-106b-5p were upregulated in the kidney of patients with DN compared with normal controls, respectively. PTGER3 and MMP-2 were targeted by drugs including iloprost, treprostinil, or captopril, and the deregulation of the two genes was confirmed in the plasma samples from patients with DN as compared with controls. Conclusions: We speculated that the RP11-363E7.4/TTN-AS1/HOTAIRM1-hsa-miR-106b-5p-PTGER3 and LINC00960-hsa-miR-1237-3p-MMP-2 networks were associated with diabetic renal injury.

10 August 2020 in Oncology Reports
Verified
Journal Article
Open access
PDF file
LMLingjun Meng
Lingjun Meng
XYXiaojing Yue
Xiaojing Yue
DZDi Zhou
Di Zhou
HLHongjun Li
Hongjun Li
Breast cancer is the most common invasive cancer in women with the highest number of related deaths which is caused by distal metastasis. Recently, integrated analysis of gene expression profile suggested widespread gene dysregulation in various types of cancer. Research in the past decade has focused on long non‑coding RNAs (lncRNAs), particularly in cell proliferation, tumor progression and metastasis. OPA‑interacting protein 5 antisense transcript 1 (OIP5‑AS1) is an evolutionarily conserved long non‑coding RNA that has been linked to oncogenesis in multiple cancers. In breast cancer, dysregulation of OIP5‑AS1 was reported but the precise role in cancer development and progression remains unclear. In the present study, using small interfering RNA (siRNA) targeting OIP5‑AS1, it was shown that knockdown of OIP5‑AS1 was associated with alteration of EMT markers and suppressed migration and invasion of breast cancer cells. Among the EMT‑related transcription factors, ZEB1 and ZEB2 were significantly downregulated with OIP5‑AS1 knockdown. Computational analysis and a dual‑luciferase reporter system identified miR‑340‑5p was the target gene for OIP5‑AS1. Further experiments verified the function of OIP5‑AS1 in cell invasion was dependent on miR‑340a‑5p through regulating target gene ZEB2. In vivo study demonstrated that overexpressing OIP5‑AS1 in breast cancer cells promoted lung metastasis in nude mice. The findings of the present study revealed the mechanism of OIP5‑AS1 in breast cancer metastasis. Overall, our study may provide a potential therapeutic target for breast cancer metastasis.

1 January 2020 in Renal Failure
Verified
Journal Article
Open access
YJYuan-Yuan Jia
Yuan-Yuan Jia
YYYue Yu
Yue Yu
HLHongjun Li
Hongjun Li
The continuous accumulation of extracellular matrix will eventually lead to glomerular sclerosis, interstitial fibrosis, tubular atrophy and vascular sclerosis, which are involved in the progression of chronic kidney disease (CKD). If these processes can be discovered early and effective interventions given in time, the progression of kidney disease may be delayed. Therefore, exploring new biomarkers and therapeutic targets that can identify CKD at an early stage is urgently needed. In recent years, studies have shown that urine periostin may be used as a marker of early renal tubular injury. And in an animal model experiment of hypertensive nephropathy, periostin is involved in the progression of kidney injury and reflects its progression. Here we review the current progress on the role of periostin in pathologic pathways of kidney system to explore whether periostin is a potential therapeutic target for the treatment of CKD.